These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 32909660

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia.
    Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, Busse WW, Wenzel S, Wu Y, Datta V, Kolbeck R, Molfino NA.
    J Allergy Clin Immunol; 2013 Nov; 132(5):1086-1096.e5. PubMed ID: 23866823
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial.
    De Boever EH, Ashman C, Cahn AP, Locantore NW, Overend P, Pouliquen IJ, Serone AP, Wright TJ, Jenkins MM, Panesar IS, Thiagarajah SS, Wenzel SE.
    J Allergy Clin Immunol; 2014 Apr; 133(4):989-96. PubMed ID: 24582316
    [Abstract] [Full Text] [Related]

  • 27. HFA-BDP Metered-Dose Inhaler Exhaled Through the Nose Improves Eosinophilic Chronic Rhinosinusitis With Bronchial Asthma: A Blinded, Placebo-Controlled Study.
    Kobayashi Y, Yasuba H, Asako M, Yamamoto T, Takano H, Tomoda K, Kanda A, Iwai H.
    Front Immunol; 2018 Apr; 9():2192. PubMed ID: 30337921
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody.
    Silkoff PE, Romero FA, Gupta N, Townley RG, Milgrom H.
    Pediatrics; 2004 Apr; 113(4):e308-12. PubMed ID: 15060258
    [Abstract] [Full Text] [Related]

  • 30. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial.
    Kelsen SG, Agache IO, Soong W, Israel E, Chupp GL, Cheung DS, Theess W, Yang X, Staton TL, Choy DF, Fong A, Dash A, Dolton M, Pappu R, Brightling CE.
    J Allergy Clin Immunol; 2021 Sep; 148(3):790-798. PubMed ID: 33872652
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.
    Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, Robinson D, Wenzel S, Busse W, Hansel TT, Barnes NC, International Mepolizumab Study Group.
    Am J Respir Crit Care Med; 2007 Dec 01; 176(11):1062-71. PubMed ID: 17872493
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
    Lee LA, Bailes Z, Barnes N, Boulet LP, Edwards D, Fowler A, Hanania NA, Kerstjens HAM, Kerwin E, Nathan R, Oppenheimer J, Papi A, Pascoe S, Brusselle G, Peachey G, Sule N, Tabberer M, Pavord ID.
    Lancet Respir Med; 2021 Jan 01; 9(1):69-84. PubMed ID: 32918892
    [Abstract] [Full Text] [Related]

  • 36. Benefit from anti-inflammatory treatment during clinical remission of atopic asthma.
    van den Toorn LM, Prins JB, de Jongste JC, Leman K, Mulder PG, Hoogsteden HC, Overbeek SE.
    Respir Med; 2005 Jun 01; 99(6):779-87. PubMed ID: 15878496
    [Abstract] [Full Text] [Related]

  • 37. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
    FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, Gilmartin G, Werkström V, Aurivillius M, Goldman M, CALIMA study investigators.
    Lancet; 2016 Oct 29; 388(10056):2128-2141. PubMed ID: 27609406
    [Abstract] [Full Text] [Related]

  • 38. Biomarkers and clinical outcomes after tezepelumab cessation: Extended follow-up from the 2-year DESTINATION study.
    Brightling CE, Caminati M, Llanos JP, Caveney S, Kotalik A, Griffiths JM, Lundahl A, Israel E, Pavord ID, Wechsler ME, Porsbjerg C, Corren J, Gołąbek M, Martin N, Ponnarambil S.
    Ann Allergy Asthma Immunol; 2024 Sep 29; 133(3):310-317.e4. PubMed ID: 38697286
    [Abstract] [Full Text] [Related]

  • 39. Phase 2a, randomized, double-blind, placebo-controlled, multicentre, parallel-group study of an H4 R-antagonist (JNJ-39758979) in adults with uncontrolled asthma.
    Kollmeier AP, Greenspan A, Xu XL, Silkoff PE, Barnathan ES, Loza MJ, Jiang J, Zhou B, Chen B, Thurmond RL.
    Clin Exp Allergy; 2018 Aug 29; 48(8):957-969. PubMed ID: 29682796
    [Abstract] [Full Text] [Related]

  • 40. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
    Chipps BE, Newbold P, Hirsch I, Trudo F, Goldman M.
    Ann Allergy Asthma Immunol; 2018 May 29; 120(5):504-511.e4. PubMed ID: 29409951
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.